Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
Connor A. Tsuchida, Nadav Brandes, Raymund Bueno, et al.
Cell (2023) Vol. 186, Iss. 21, pp. 4567-4582.e20
Open Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

Past, present, and future of CRISPR genome editing technologies
Martin Pacesa, Oana Pelea, Martin Jínek
Cell (2024) Vol. 187, Iss. 5, pp. 1076-1100
Open Access | Times Cited: 119
CAR-T cell manufacturing: Major process parameters and next-generation strategies
Melanie Ayala Ceja, Mobina Khericha, Caitlin Harris, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 2
Open Access | Times Cited: 62
A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells
Victor Tieu, Elena Sotillo, Jeremy Bjelajac, et al.
Cell (2024) Vol. 187, Iss. 5, pp. 1278-1295.e20
Closed Access | Times Cited: 40
Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology
Ruiyu Tao, Xiaopeng Han, Xue Bai, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 25
Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?
Caroline Lonez, Eytan Breman
Cells (2024) Vol. 13, Iss. 2, pp. 146-146
Open Access | Times Cited: 17
High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing
Nathan H. Lazar, Safiye Çelik, Lu Chen, et al.
Nature Genetics (2024) Vol. 56, Iss. 7, pp. 1482-1493
Open Access | Times Cited: 17
Targeted nonviral delivery of genome editors in vivo
Connor A. Tsuchida, Kevin Wasko, Jennifer Hamilton, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 11
Open Access | Times Cited: 16
Epigenome editing technologies for discovery and medicine
Sean R. McCutcheon, Dahlia Rohm, Nahid Iglesias, et al.
Nature Biotechnology (2024) Vol. 42, Iss. 8, pp. 1199-1217
Closed Access | Times Cited: 16
CRISPR/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review
Emir Begagić, Hakija Bečulić, Nermin Đuzić, et al.
Biomedicines (2024) Vol. 12, Iss. 1, pp. 238-238
Open Access | Times Cited: 15
Heparin Specifically Inhibits CRISPR/Cas12 Activation, Enabling Ultrasensitive Heparin Detection and Gene Editing Regulation
Min Cao, Xinlan Bian, Zhirun Ji, et al.
Analytical Chemistry (2024) Vol. 96, Iss. 9, pp. 3970-3978
Closed Access | Times Cited: 13
CRISPR–Cas9 applications in T cells and adoptive T cell therapies
Xiaoying Chen, Shuhan Zhong, Yonghao Zhan, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 13
Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy
Tao Lei, Yazhuo Wang, Yuchen Zhang, et al.
Leukemia (2024)
Open Access | Times Cited: 11
CD5 deletion enhances the antitumor activity of adoptive T cell therapies
Ruchi P. Patel, Guido Ghilardi, Yunlin Zhang, et al.
Science Immunology (2024) Vol. 9, Iss. 97
Closed Access | Times Cited: 9
Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting
Danqing Zhu, Wonjoon Kim, Hyunjin Lee, et al.
Advanced Materials (2025)
Closed Access | Times Cited: 1
Triple knockdown of CD11a , CD49d , and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice
Hongye Wang, Zhaorong Wu, Dan Cui, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 782
Closed Access | Times Cited: 1
Targeted Delivery of mRNA with Polymer–Lipid Nanoparticles for In Vivo Base Editing
Qimingxing Chen, Yan Chang, Xiaoyan He, et al.
ACS Nano (2025)
Closed Access | Times Cited: 1
Decoding heterogeneous single-cell perturbation responses
Bicna Song, Dingyu Liu, Weiwei Dai, et al.
Nature Cell Biology (2025)
Open Access | Times Cited: 1
Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells
Srishti U. Sahu, Madalena Castro, Joseph J. Muldoon, et al.
Nature Protocols (2025)
Open Access | Times Cited: 1
Compact CRISPR genetic screens enabled by improved guide RNA library cloning
Seok‐Jin Heo, Lauren D. Enriquez, Scot Federman, et al.
Genome biology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 7
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance
Nils Wellhausen, Joanne Seoyoung Baek, Saar Gill, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 9, pp. 614-628
Closed Access | Times Cited: 7
Modulation of the microhomology-mediated end joining pathway suppresses large deletions and enhances homology-directed repair following CRISPR-Cas9-induced DNA breaks
Baolei Yuan, Chongwei Bi, Yeteng Tian, et al.
BMC Biology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells
Arianna Moiani, Gil Letort, Sabrina Lizot, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases
Daniel Baker, Carl H. June
Cell (2024) Vol. 187, Iss. 18, pp. 4826-4828
Closed Access | Times Cited: 6
Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations
Grégoire Cullot, Eric J. Aird, Moritz F. Schlapansky, et al.
Nature Biotechnology (2024)
Open Access | Times Cited: 6
CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy
Valentine De Castro, Jeanne Galaine, Romain Loyon, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 8, pp. 1124-1134
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top